事件 公司发布2025 半年度报告，上半年实现营业收入3.55 亿元（+74%），净亏损收窄至3.79 亿元，销售费 用率76%（-24pts），现金及现金等价物达22.51 亿元（+172%）。医保赋能双产品快速放量，商业化收 入增长强劲，亏损进一步缩窄。 核心观点 舒沃替尼一线全球III 期入组完成，临床与适应症拓展双线并进舒沃替尼作为全球首个口服EGFR Exon20ins 抑制剂，不仅在中国和美国获批，还成功进入NCCN 推荐，显示出全球临床价值。其一线全 球III 期注册研究已完成入组，并同步拓展耐药NSCLC 及其他适应症领域，最新数据将在2025 WCLC 披露，注册与适应症拓展齐头并进。 高瑞哲疗效显著，积极推进联用实验 高瑞哲在r/r PTCL 治疗中获CSCO 指南I 级推荐，单药治疗r/r NKTCL首次获得推荐，针对PTCL 维持治 疗获得认可，凭借优异疗效，有望在全球PTCL 市场形成领先优势。同时，公司积极推进高瑞哲与PD-1 联合用于耐药NSCLC 的研究探索，正逐步打开实体瘤应用前景。 管线布局多点开花，创新产品储备丰富 Birelentinib（DZD8586）作为全球首个完 ...

迪哲（江苏）医药股份有限公司 关于 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，践行以投资者为本的理念， 推动上市公司持续优化经营、规范治理和积极回报投资者，迪哲（江苏）医药股份 有限公司（简称"公司"）于 2025 年 4 月 30 日发布了《关于 2024 年度"提质增效 重回报"行动方案的年度评估报告以及推动 2025 年度"提质增效重回报"行动方 案》（以下简称"《行动方案》"）。公司根据《行动方案》内容，积极开展和落 实各项工作，现将 2025 年上半年的主要工作成果评估报告如下： 一、舒沃哲美国获批，核心产品加速前行 公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法 的研究、开发和商业化。公司坚持源头创新的研发理念，以推出全球首创药物 （First-in-class）和具有突破性潜力的治疗方法为目标，旨在填补全球未被满足的 临床需求。报告期内，公司持续创新研发投入，提升全球竞争力，2025 年上半年 研发投入达 4.08 亿，2025 年上半年主要产品取得了令人鼓舞的进展： ZEGFROVY ）的新药上市申请（New ...

Group 1 - The core viewpoint of the articles highlights the significant revenue growth and commercialization progress of DiZhe Pharmaceutical, with a reported revenue of 360 million yuan in 2024, marking a year-on-year increase of 294.24% [1] - The company has successfully launched two commercialized products, which have seen nearly doubled sales revenue, achieving a year-on-year growth of 96% in the first quarter of this year [1] - DiZhe Pharmaceutical has established a competitive product pipeline with seven products, including two that are in global clinical trials and have been approved for marketing in China [1][2] Group 2 - In 2024, the company invested 724 million yuan in R&D, accounting for 201.08% of its revenue, with an additional 210 million yuan spent in the first quarter [2] - The company plans to allocate nearly 1 billion yuan from its recent fundraising to the development of core pipeline drugs, including Shuwotini and DZD8586 [2] - DiZhe Pharmaceutical's innovative drug development is characterized by long cycles and high costs, with potential uncertainties in future sales revenue due to various market factors [3] Group 3 - The company is expected to remain unprofitable in the short term, with cumulative losses likely to increase due to ongoing investments in drug registration and market promotion [3] - Analysts believe that DiZhe Pharmaceutical's focus on oncology and innovative products will drive rapid growth in performance as commercialized products gain market traction [3]